The Commercial Role Is Not Disappearing. It Is Being Repriced.
AI can generate the deck, draft the business case, and summarize the literature. If that is what your commercial team does, you have a positioning problem, not a technology problem.
Here is the thing that is making commercial leaders in MedTech nervous right now, whether they say it out loud or not:
AI can generate the deck. AI can draft the business case. AI can summarize the clinical literature, map the stakeholders, and outline the objection-handling sequence.
If that is what your commercial team does, you have a positioning problem. Not a technology problem.
I published a piece this week that makes one core argument: the value of knowledge work was never in producing the artifact. It was in reducing uncertainty for the person who had to make the decision. AI generates artifacts. It does not reduce uncertainty. That is still a human job.
The distinction matters more in MedTech than almost anywhere else.
Here is why.
The buying environment in medical technology is not a transaction. It is a committee. An IDN acquisition runs through clinical champions, supply chain, value analysis, the CFO's office, and legal, sometimes in that order, sometimes simultaneously, always with competing definitions of value. The artifact (the proposal, the business case, the ROI model) is the entry ticket. It is not the deal.
What closes the deal is someone who can do five things an AI cannot:
Frame the problem in a way that survives internal scrutiny. Identify which stakeholder's resistance is structural versus positional. Build a case that speaks Clinical to the physician, Operational to the administrator, and Financial to the CFO, simultaneously, without contradiction. Navigate the political surface that sits between a champion's enthusiasm and a committee's approval. Own the downside when it does not go as planned.
Those five things are not outputs. They are judgment calls made under uncertainty, with incomplete information, on behalf of someone who cannot afford to get it wrong.
That is what commercial leaders are paid to do. AI does not threaten that. It raises the floor on everything below it.
What it does threaten is the commercial role that is built on producing information rather than converting uncertainty. The rep who succeeds because he has the best product collateral, or knows the clinical literature better than the physician, or can build a more detailed ROI spreadsheet than the customer, that rep is now competing with a tool that never sleeps, never has a bad quarter, and does not need a territory.
The commercial teams that will win over the next three years are not the ones that adopt AI the fastest. They are the ones that understand what their role actually is, and build accordingly.
The artifact is a commodity. The judgment is not.
If you work in healthcare commercial operations, as a leader, a strategist, or a seller, the question below is worth sitting with.
One question to sit with over the weekend:
In your commercial organization, what percentage of the week is spent producing information versus reducing the uncertainty that surrounds a decision?
That ratio is the single most important thing AI will change about how commercial teams are built and measured.
Dr. Gunter Wessels is the founder of LiquidSMARTS℠, a commercial engineering firm that helps high-tech healthcare suppliers accelerate pipeline velocity. LiquidSMARTS℠ guarantees a 10% improvement in pipeline velocity within 90 days.